09:24 AM EDT, 07/03/2025 (MT Newswires) -- Clearmind Medicine ( CMND ) said Thursday its ongoing phase 1/2a clinical trial assessing oral drug candidate CMND-100 in alcohol use disorder has received institutional review board approval from Tel Aviv Sourasky Medical Center in Israel.

The approval will allow patient enrollment at the medical center before the start of the first-in-human trial at the site, the company said.

The company's shares were up 31% in recent premarket activity.